Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) went up by 7.62% during the previous trading session, and it is maintaining the win ahead of Tuesday’s trading session. The share price of the Biotechnology giant went up by $35.75 to trade ended Tuesday trading at $33.22. This is up from the $33.22 price recorded on Monday’s trading session. Thanks to this latest performance, ARWR is closer to the higher price 52-week target of $81.00 and further from the lowest price target of $29.00. Its performance from the start of the year has also been negative, with ARWR down by -43.64% year-to-date.
Arrowhead Pharmaceuticals Inc. (ARWR) started the day trading at $34.2 and recorded an intraday high of $36.1671. It also recorded an intraday low of $33.6175 during Tuesday’s trading session. Arrowhead Pharmaceuticals Inc. is a very active stock that recorded a trading volume that is less than -17.4% of the average daily trading volume on Tuesday. The stock’s trading volume on Tuesday was 1158448, which is less than -17.4 of the total average daily trading volume of 1.36 million.
Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) 2020 Performance Impressive
The increase in ARWR’s stock price on Tuesday saw its overall performance boost over the past few months. We can quantify the performance of the stock so far this year using a few metrics. The 52-week high price of ARWR currently stands at $73.72, which is higher than the current trading price of the stock by 51.51%. However, ARWR’s current trading price is -83.24% lower than the 52-week low price of $19.51. In terms of trading volume, Arrowhead Pharmaceuticals Inc. currently experienced healthy participation during the last trading session. 1158448 shares of Arrowhead Pharmaceuticals Inc. were traded on the stock exchange on Tuesday, which is less than -17.4% of the 1.36 million average trading volume of the stock.
The performance of the stock has been positive over the past year. ARWR’s performance over the past one year has seen it surge by 35.16%, while the stock has gone down by -46.21% in the last six months. The quarterly performance of ARWR currently stands at 62.72%, and it is down by -0.28% in the last month. The only positive figure was from the weekly performance, which currently reads 1.74%. At the time of writing ARWR’s report, the company has a total market cap of $3.51B, making it one of the largest publicly-traded companies in the world.Arrowhead Pharmaceuticals Inc. also has over 134 employees all over the world.
ARWR Insider Activities
For Arrowhead Pharmaceuticals Inc., insiders hold 65.50% of all company shares. The insider transactions over the past six months are up by 78.40%. During that period, insiders bought 1,544,520 shares in 32 transactions. In that same period, insiders sold 310,912 of their shares in 36 transactions. After these transactions, insiders at Arrowhead Pharmaceuticals Inc. now hold 2.81M shares, which is over 63.91% of the total company stocks. Institutional investors currently hold a large chunk of the ARWR shares, as they control 2.76% of the company’s total stock.
ARWR Fundamental Analysis
For Arrowhead Pharmaceuticals Inc., the stock’s diluted earnings per share (EPS) stands at 0.10. In the coming year, analysts expect the EPS to be -0.97. The EPS growth will up over the next five years to 7.33% after surging by 20.60% in the previous five years. In terms of revenue, Arrowhead Pharmaceuticals Inc.’s quarterly sales (YOY) is shrinking at -0.11, which is lower than the average annual revenue of 20.60% over the past half a decade.
The Return on Investment (ROI) on Arrowhead Pharmaceuticals Inc.’s stock currently stands at 24.90%, and it has a net profit margin of 6.90%. The operating margin of the company is 0.80%.
ARWR Analysts Prediction
Another analyst that has a Overweight rating for ARWR is Cantor Fitzgerald, which set a price target of between $55 and $60.
Chardan Capital Markets and B. Riley FBR also believe that Arrowhead Pharmaceuticals Inc.’s stock is outperforming at the moment.
At the moment, Arrowhead Pharmaceuticals Inc.’s Total Debt to Equity ratio stands at 0.00, and they have a long-term Debt to Equity ratio of 0.00.
ARWR Technical Analysis
The Simple Moving Average (SMA) is one of the most powerful technical indicators. The 20-day Simple Moving Average of ARWR currently stands at 4.59%, while the SMA50 is 3.16%. The biggest one is the SMA200, which is currently reading -11.99% ahead of Tuesday’s trading session. The Relative Strength Index of this stock is 54.19, while its price to earnings ratio (P/E) is 361.11.